Congestive heart failure and arrhythmias: Therapeutic modalities

Journal of Cardiovascular Electrophysiology

Volumn 8, Issue 1, 1997, Pages 89-97

  Singh, Steven N ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

aspirin; beta blockers; calcium channel blockers; contractility agents; potassium channel blockers; revascularization; sudden death; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM CHANNEL BLOCKING AGENT; VASODILATOR AGENT; WARFARIN;

CONGESTIVE HEART FAILURE; ELECTROPHYSIOLOGY; HEART ARRHYTHMIA; HEART MUSCLE REVASCULARIZATION; MORTALITY; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH;

EID: 0031043735     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1997.tb00613.x     Document Type: Review

References (61)

1. Garg R, Packer M, Pitt B, et al: Heart failure in the 1990's: Evolution of a major public health problem in cardiovascular medicine. J Am Coll Cardiol 1993;22 (Suppl A):3A-5A.
2. Ho K, Pinsky J, Kannel W, et al: The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993;22(Suppl A):6A-13A.
3. Massie B, Francis G, Tandon P, et al: Asymptomatic ventricular arrhythmias do not identify patients with severe heart failure at risk for sudden death. J Am Coll Cardiol 1993;21(Suppl):459A.
4. Singh SN, Fletcher RD, Fisher SG, et al: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333:77-82.
5. Cohn JN, Archibald DG, Franciosa SA, et al: Effects of vasodilator therapy on mortality in chronic congestive heart failure: A result of a Veterans Affairs Cooperative Study (V-HeFT). N Engl J Med 1986;314: 1547-1552.
6. Cohn JN, Johnson G, Ziesihe S, et al: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
7. Luu M, Stevenson WG, Stevenson LW, et al: Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989;80:1675-1680.
8. Levy D, Garrison RJ, Savage DD, et al: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-1566.
9. Tomaselli GF, Beuckelmann DJ, Calkin HG, et al: Sudden death in heart failure: The role of abnormal repolarization. Circulation 1994;90:2534-2539.
10. Hansen DE, Craig S, Hondegheim L: Stretch-induced arrhythmias in the isolated canine ventricle: Evidence for the importance of mechano-electrical feedback. Circulation 1990;81:1094-1105.
11. Franz M: Stretch activated arrhythmias. In Zipes DP, Jalife J, eds: Cardiac Electrophysiology: From Cell to Bedside. WB Saunders, Philadelphia, 1995, p. 592.
12. Simson MB: Signal-averaged electrocardiography. In Zipes DP, Jalife J, eds: Cardiac Electrophysiology: From Cell to Bedside. WB Saunders, Philadelphia, 1995, p. 1038.
13. Bigger JT: Spectral analysis of RR variability to evaluate autonomic physiology and pharmacology and to predict cardiovascular outcomes in humans. In Zipes DP, Jalife J, eds: Cardiac Electrophysiologv: From Cell to Bedside. WB Saunders, Philadelphia, 1995, p. 1151.
14. Stevenson WG, Stevenson LW, Weiss S, et al: Inducible ventricular arrhythmias and sudden death during vasodilator therapy of severe heart failure. Am Heart J 1988;116:1447-1454.
15. The Cardiac Arrhythmia Suppression Trial II Investigators: Effect of antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-233.
16. Gottlieb SS, Kukin ML, Yushak M, et al: Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure. Ann Intern Med 1989;110:505-509.
17. Pratt CM, Eaton T, Francis M, et al: The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: Dangerous imbalance in the risk-benefit ratio. Am Heart J 1989;118:433-440.
18. Singh S, Klein R, Eisenberg B, et al: Long term effect of mexiletine on left ventricular function and relation to suppression of ventricular arrhythmia. Am J Cardiol 1990;66:1222-1227.
19. IMPACT Research Group: International mexiletine and placebo antiarrhythmic coronary trial I. Report and other findings. J Am Coll Cardiol 1984;4:1148-1163.
20. Coplen S, Antman E, Berlin JA, et al: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials. Circulation 1990;82:1106-1116.
21. Flaker GC, Blackshear JL, McBride R, et al: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-532.
22. Chadda K, Goldstein S, Byington R, et al: Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-510.
23. Waagstein F, Bristow MR, Swedberg K, et al., for the Metoprolol Dilated Cardiomyopathy (MDC) Trial Study Group: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-1446.
24. CIBIS Investigators and Committees: A randomized trial of beta blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-1773.
25. Packer M, Bristow MR, Cohn JN, et al: Effect of carvedilol on the survival of patients with chronic heart failure. (Abstract) Circulation 1995;92:673.
26. Xamoterol in Severe Heart Failure Study Group: Xamoterol in severe heart failure. Lancet 1990;336:1-6.
27. Cingolani HE, Wiedmun RT. Lynch JJ, et al: Negative lusitropic effect of DP 201-106 and E4031. Possible role of prolonging action potential duration. J Mol Cell Cardiol 1990;22:1025-1034.
28. Waldo A, Camm AJ, de Ruyter H, et al: Preliminary mortality results from the survival with oral d-sotalol (SWORD) trial. (Abstract) J Am Coll Cardiol 1995;(Special issue):15A.
29. Mason JW, for the Electrophysiologic Study versus Electrocardiographic Monitoring Investigators: A comparison of electrocardiographic testing with Holter monitoring to predict antiarrhythmic drug efficacy for ventricular tachyarrhythmias. N Engl J Med 1993;329:445-451.
30. Mason JW, for the Electrophysiologic Study versus Electrocardiographic Monitoring Investigators: A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993; 329:452-458.
31. Reiffei JA, Hahn E, Hart V, and the ESVEM Investigators: Was the superiority of sotalol in the ESVEM trial due to its beta blocking effect? (Abstract) PACE 1995; 18:811.
32. Cleland JGF, Dargie HJ, Findlay JN, et al: Clinical, hemodynamic and antiarrhythmic effects of longterm treatment with amiodarone of patients in heart failure. Br Heart J 1987;57:436-445.
33. Nicklas JM, McKenna WJ, Steward RA, et al: Prospective, double-blind, placebo control trial of lowdose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J 1991;122:1010-1121.
34. Pfisterer M, Kiowski W, Burckhardt D, et al: Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. Am J Cardiol 1992;69:1399-1402.
35. Burkart F, Pfisterer M, Kiowski W, et al: Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias. Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990:16: 1171-1178.
36. Doval HC, Nul DR, Vancelli HO, et al: Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-498.
37. Nul DR, Doval HC, Grancelli HO, et al: Heart rate is a marker of amiodarone mortality reduction in severe heart failure. (Abstract) Circulation 1995;92(Suppl I):I-666.
38. Furberg CD, Psaty BM, Meyer JV: Nifedipine. Dose related increase in mortality in patients with coronary disease. Circulation 1995;92:1326-1331.
39. Packer M: The PRAISE (Prospective Randomized Amlodipine Survival Evaluation) Trial. Results: Presented at the American College of Cardiology Annual Meeting, March 1995.
40. O'Connor CM, Belkin RN, Carson PE, et al: Effect of amlodipine on mode of death in severe chronic heart failure: The PRAISE trial. (Abstract) Circulation 1995; 92:I-143.
41. Cohn JN, Ziesche SM, Loss LE, et al: Effect of felodipine on short-term exercise and neurohormonal and long-term mortality in heart failure: Results of VHeFT III. (Abstract) Circulation 1995;92(8):I-143.
42. The Multicenter Diltiazem Postinfarction Trial Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-392.
43. The Danish Study Group on Verapamil in Myocardial Infarction: Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Trial II-DAVIT II). Am J Cardiol 1990;66: 779-785.
44. Packer M, Carver SR, Rodenheffer RJ, et al: Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475.
45. Yusuf S, Teo K: Inotropic agent increase mortality in patients with congestive heart failure. (Abstract) Circulation 1990;(Suppl III):III-673.
46. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987:316:1429-1435.
47. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction and clinical evidence of heart failure. Lancet 1993;342: 821-828.
48. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Longterm Evaluation (SMILE) Study Investigators: The effect of the angiotensin-converting enzyme inhibitor on mortality and morbidity after autonomie myocardial infarction. N Engl J Med 1995;332:80-85.
49. SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
50. Pfieffer MA, Braunwald E, Moyé LA, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:667-669.
51. Fletcher RD, Archibald D, Orndorff J. et al: Dysrhythmias on short-term Holter as an independent predictor of mortality in congestive heart failure. (Abstract) J Am Coll Cardiol 1986;7:143A.
52. Pratt CM, Gardner M, Pepine C, et al: Lack of long-term ventricular arrhythmia reduction by enalapril in heart failure. Am J Cardiol 1995;75:1244-1249.
53. Dries DL, Waclawiw MA, Domanski M: Antiplatelet and anticoagulant therapy reduce the risk of sudden death in the SOLVD prevention and treatment trials. (Abstract) PACE 1996;19(Pt II)602.
54. The Anturane Reinfarction Trial Research Group: Sulfin-pyrazone in the prevention of cardiac death after myocardial infarction. N Engl J Med 1978;298:289-295.
55. ISIS 2 (Second International Study of Infarction Survival) Collaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected myocardial infarction. Lancet 1988;ii:349-360.
56. Falk RH, Pollack A, Tandon PK, et al: The effects of warfarin prevalence of stroke in patients with severe heart failure. (Abstract) J Am Coll Cardiol 1993; 21:218A.
57. Dunkman WB, Johnson GR, Carson PE, et al: Incidence of thromboembolic events in congestive heart failure. Circulation 1993;87(Suppl VI):VI-94-VI-101.
58. Holmes DR, Davis K, Gersh BJ, et al., and participants in the Coronary Artery Surgery Study: Risk factor profiles of patients with sudden death and death from other cardiac causes: A report from the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol 1989;13:524-530.
59. Garan H, Ruskin JN, DiMarco JP, et al: Electrophysiologic studies before and after myocardial revascularization in patients with life-threatening ventricular arrhythmias. Am J Cardiol 1983;51:519-524.
60. Hii JT, Traboulsi M, Mitchell LB, et al: Infarct artery patency predicts outcome of serial electropharmacological studies in patients with malignant tachyarrhythmias. Circulation 1993;87:764-772.
61. Kuck KH, et al: Hamburg Cardiac Arrest Study Group. (Abstract) Rev Eur Tech Biomed 1990;12:110.